SCHEMBL560158

SCHEMBL560158

C=Cc1cc(Cl)ccc1[C@@H]1CNC(=O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.44
PDE4A P27815 12/20 0.40
PDE4B Q07343 7/20 0.40
PDE4C Q08493 7/20 0.40
PDE4D Q08499 7/20 0.40
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 1/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
SLC6A3 Q01959 3/20 0.35
SLC6A2 P23975 2/20 0.35
TSHR P16473 1/20 0.34
CYP3A4 P08684 2/20 0.34
VEGFA P15692 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
CREBBP Q92793 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560148 0.87 MTNR1A (0.46) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL559927 0.80 MTNR1A (0.46) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL559928 0.80 MTNR1A (0.46) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL20177704 0.78 MTNR1A (0.48) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL560175 0.78 MTNR1A (0.48) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL559629 0.78 MTNR1A (0.48) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL559712 0.78 MTNR1A (0.48) MTNR1APDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL560453 0.77 MTNR1A (0.47) MTNR1APDE4APDE4BPDE4CPDE4D
SCHEMBL16952146 0.76 TAAR1 (0.40) ALDH1A1CHRNB2CHRNA4SLC6A3SLC6A2
SCHEMBL564310 0.74 SLC6A3 (0.53) MTNR1APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344028-B2 Gamma-amino-butyric acid derivatives as GABAB receptor ligands XENOPORT, INC. (US) 2013-01-01 US disclosed
EP-2419401-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS XenoPort, Inc. (US) 2012-02-22 EP disclosed
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2012-02-09 US disclosed
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2010-10-21 US disclosed
WO-2010120370-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 MTNR1A 394/4885PDE4A 1099/4885PDE4B 742/4885
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 MTNR1A 394/4885PDE4A 1099/4885PDE4B 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.